Acura Pharmaceuticals Inc (ACUR)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Acura Pharmaceuticals Inc (ACUR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8012266
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月14日
◆ページ数:45
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Acura Pharmaceuticals Inc (Acura) is a specialty pharmaceutical company that researches, develops, and commercializes tamper-resistant products to prevent the abuse and misuse of medication. The company’s proprietary technologies, Aversion, Limitx and Impede, are used to prevent product tampering associated with opioid abuse. Its Impede technology helps minimize the extraction and conversion of pseudoephedrine into methamphetamine. Limitx reduces the level of opioid release when several tablets are swallowed. Aversion irritates the nasal passages upon snorting the product Its product portfolio includes Oxaydo, an opioid analgesic; Nexafed and Nexafed Sinus Pressure plus that contain pseudoephedrine. The company markets its products in the US and Canada. Acura is headquartered in Palatine, Illinois, the US.

Acura Pharmaceuticals Inc (ACUR) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Acura Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Acura Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Acura Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Acura Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Acura Pharmaceuticals Inc, Medical Devices Deals, 2011 to YTD 2017 11
Acura Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12
Acura Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 13
Licensing Agreements 13
MainPointe Pharma Enters into Licensing Agreement with Acura Pharma 13
KemPharm Enters into Licensing Agreement with Acura Pharma 15
Egalet Enters into Licensing Agreement with Acura Pharma 16
Equity Offering 17
Acura Pharma Raises USD4 Million in Private Placement of Units 17
Acura Pharmaceuticals Files Registration Statement for Public Offering of Shares 18
Acura Pharma Raises USD7.6 Million in Private Placement of Shares 19
Acura Pharma Completes Second Tranche Of Public Offering Of Shares For US$3.4 Million 21
Acquisition 22
Acura Pharma Plans to Sell Itself 22
Acura Pharmaceuticals Inc – Key Competitors 23
Acura Pharmaceuticals Inc – Key Employees 24
Acura Pharmaceuticals Inc – Locations And Subsidiaries 25
Head Office 25
Other Locations & Subsidiaries 25
Recent Developments 26
Financial Announcements 26
Nov 13, 2017: Acura Pharmaceuticals Announces Third Quarter 2017 Financial Results 26
Aug 14, 2017: Acura Pharmaceuticals Announces Second Quarter 2017 Financial Results 27
May 12, 2017: Acura Pharmaceuticals Announces First Quarter 2017 Financial Results 28
Mar 31, 2017: Acura Pharmaceuticals Announces Fourth Quarter 2016 and Full Year 2016 Financial Results 29
Nov 14, 2016: Acura Pharmaceuticals Announces Third Quarter 2016 Financial Results 30
Aug 08, 2016: Acura Pharmaceuticals Announces Second Quarter 2016 Financial Results 31
May 02, 2016: Acura Pharmaceuticals Announces First Quarter 2016 Financial Results 32
Feb 29, 2016: Acura Pharmaceuticals Announces Fourth Quarter and Full Year 2015 Financial Results 33
Product News 34
09/11/2017: Acura Pharmaceuticals Presenting New LIMITx Clinical Data at the 19th Annual Rodman & Renshaw Conference 34
07/11/2016: Acura Pharmaceuticals to Host Webcast on July 14, 2016 to Discuss Additional Data From Study AP-LTX-400 35
06/28/2017: Acura Pharmaceuticals Advances LTX-04 and its LIMITx Technology 36
04/13/2016: Acura Pharmaceutical Limitx Technology Successfully Demonstrates Oral Abuse Deterrence 37
Product Approvals 39
Dec 14, 2016: Acura Pharmaceutical Provides Development Update on its LIMITx Technology 39
Apr 12, 2016: Acura Pharmaceuticals Announces FDA Fast Track Designation for the Development of LTX-04 40
Clinical Trials 41
May 18, 2017: Acura Pharmaceutical Initiates Second Clinical Study on LTX-04 41
Jun 08, 2016: Acura Pharmaceuticals LIMITX(TM) Technology Successfully Confirms Oral Abuse Deterrence Capabilities 42
Feb 01, 2016: Acura Pharmaceuticals Provides Development Update on Its oral abuse deterrent drug LIMITX 44
Appendix 45
Methodology 45
About GlobalData 45
Contact Us 45
Disclaimer 45

List of Tables
Acura Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Acura Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Acura Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Acura Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Acura Pharmaceuticals Inc, Deals By Therapy Area, 2011 to YTD 2017 9
Acura Pharmaceuticals Inc, Medical Devices Deals, 2011 to YTD 2017 11
Acura Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12
MainPointe Pharma Enters into Licensing Agreement with Acura Pharma 13
KemPharm Enters into Licensing Agreement with Acura Pharma 15
Egalet Enters into Licensing Agreement with Acura Pharma 16
Acura Pharma Raises USD4 Million in Private Placement of Units 17
Acura Pharmaceuticals Files Registration Statement for Public Offering of Shares 18
Acura Pharma Raises USD7.6 Million in Private Placement of Shares 19
Acura Pharma Completes Second Tranche Of Public Offering Of Shares For US$3.4 Million 21
Acura Pharma Plans to Sell Itself 22
Acura Pharmaceuticals Inc, Key Competitors 23
Acura Pharmaceuticals Inc, Key Employees 24
Acura Pharmaceuticals Inc, Other Locations 25
Acura Pharmaceuticals Inc, Subsidiaries 25

★海外企業調査レポート[Acura Pharmaceuticals Inc (ACUR)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • The Aerospace Corp:企業の戦略的SWOT分析
    The Aerospace Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and ser …
  • Mitsui & Co., Ltd.:企業のM&A・事業提携・投資動向
    Mitsui & Co., Ltd. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Mitsui & Co., Ltd. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), d …
  • Ansell Limited (ANN):医療機器:M&Aディール及び事業提携情報
    Summary Ansell Limited (Ansell) is a provider of protection solutions. It develops, manufactures and markets a broad range of hand and arm protection solutions and hospital clothing. It also offers medical gloves and healthcare and industrial safety solutions. Ansell offers its products to healthcar …
  • PledPharma AB (PLED):企業の財務・戦略的SWOT分析
    Summary PledPharma AB (PledPharma) is a pharmaceutical company that discovers, manufactures, and develops drugs that protect the body against oxidative stress. The company discovers and develops Aladote and PledOx drugs. PledOX drug is used to prevent chemotherapy-induced side effects for colorectal …
  • Probiodrug AG (PBD):企業の財務・戦略的SWOT分析
    Summary Probiodrug AG (Probiodrug) is a clinical stage biopharmaceutical company that conducts research and development of new medicines for the treatment of Alzheimer’s disease. The company provides three pipeline drug candidates such as PQ912, PBD-C06 and PQ1565. Its PQ912 drug candidate is a smal …
  • Concur Technologies Inc:企業の戦略的SWOT分析
    Concur Technologies Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • Cameco Corporation:企業の戦略・SWOT・財務情報
    Cameco Corporation - Strategy, SWOT and Corporate Finance Report Summary Cameco Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Twenty-First Century Fox Inc. (FOXA):企業の財務・戦略的SWOT分析
    Twenty-First Century Fox Inc. (FOXA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Taylor Wessing LLP:企業の戦略・SWOT・財務情報
    Taylor Wessing LLP - Strategy, SWOT and Corporate Finance Report Summary Taylor Wessing LLP - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Holland Board of Public Works:企業の戦略的SWOT分析
    Holland Board of Public Works - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produ …
  • West Corporation:企業の戦略的SWOT分析
    West Corporation - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • Energy Transfer LP:企業の戦略・SWOT・財務分析
    Energy Transfer LP - Strategy, SWOT and Corporate Finance Report Summary Energy Transfer LP - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Safeguard Scientifics Inc (SFE):企業の財務・戦略的SWOT分析
    Summary Safeguard Scientifics Inc (Safeguard Scientifics), formerly Lancaster Corp, is a provider of finance, healthcare and digital media solutions. The company offers business intelligence and analytics for institutional/capital markets, insurance technology, regulatory and compliance technology a …
  • Tokyo Gas Co., Ltd.:企業の戦略・SWOT・財務情報
    Tokyo Gas Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Tokyo Gas Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Brazos Electric Cooperative, Inc.:企業の戦略的SWOT分析
    Brazos Electric Cooperative, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major p …
  • iRobot Corp (IRBT):企業の財務・戦略的SWOT分析
    iRobot Corp (IRBT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • UGI Corporation:企業の戦略・SWOT・財務情報
    UGI Corporation - Strategy, SWOT and Corporate Finance Report Summary UGI Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • pSivida Corp (PSDV)-医療機器分野:企業M&A・提携分析
    Summary pSivida Corp (pSivida) is a specialty pharmaceutical company that offers development of miniaturized, sustained-release drug delivery products and technologies. The company’s products include iluvien, retisert and durasert. Its durasert is an injectable, miniaturized, sustained-release drug …
  • Palred Technologies Ltd:企業の戦略・SWOT・財務分析
    Palred Technologies Ltd - Strategy, SWOT and Corporate Finance Report Summary Palred Technologies Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • China North Industries Corporation:企業の戦略・SWOT・財務情報
    China North Industries Corporation - Strategy, SWOT and Corporate Finance Report Summary China North Industries Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆